Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:35:267-285.
doi: 10.1007/978-3-031-45493-6_14.

Endogenous and Exogenous Opioids: Role in Substance Use Disorders

Lindsay Acree  1
Affiliations
Review

Endogenous and Exogenous Opioids: Role in Substance Use Disorders

Lindsay Acree. Adv Neurobiol. 2024.

Abstract

Opioid use disorders have become an epidemic in recent years with rates nearly quadrupling since 1999 according to the US Centers for Disease Control and Prevention (Centers for Disease Control, Wide-ranging online data for epidemiologic research (WONDER). CDC, National Center for Health Statistics, Atlanta. Retrieved December 19, 2017, from http://wonder.cdc.gov, 2016). To understand substance use disorder (SUD) as a disease, many aspects must be studied including the circuitry in the brain, adaptations to neuronal circuitry and neurotransmitters, genetic variations increasing the risk for SUD, and treatments available for SUD. The mechanism in which an exogenous opioid may cause SUD is nearly identical to the mechanism of an endogenous opioid. This chapter reviews the clinical and epidemiological aspects of opioid use disorder, as well as the interactions between endogenous and exogenous opioids. Additionally, this chapter discusses current scientific data regarding genetic variations and mechanisms within brain circuitry and the role of endogenous opioids in substance use disorders generally (and opioid use disorder specifically). Future applications of these data to treatment of substance use disorders are also discussed.

Keywords: Addiction; Endogenous opioids; Exogenous opioids; Naloxone; Opioid receptor; Substance use disorder.

PubMed Disclaimer

References

    1. Alkermes, Inc. (2010). Vivitrol (naltrexone for extended-release injectable suspension) package insert. Retrieved December 1, 2017, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf
    1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing. - DOI
    1. Berde, C. B., Beyer, J. E., Bournaki, M. C., Levin, C. R., & Sethna, N. F. (1991). Comparison of morphine and methadone for prevention of postoperative pain in 3- to 7-year-old children. The Journal of Pediatrics, 119(1 Pt 1),136–41.
    1. Blazes, C. K., & Morrow, J. D. (2020). Reconsidering the usefulness of adding naloxone to buprenorphine. Frontiers in Psychiatry, 11, 549272. - DOI - PubMed - PMC
    1. Bruchas, M. R., Land, B. B., & Chavkin, C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Research, 1314, 44–55. - DOI - PubMed

MeSH terms

LinkOut - more resources